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Abstract
Purpose of review Precision medicine is an evolving field stemming from Oncology re-
search, with an increasingly important role in autoimmune diseases. The heterogeneity,
both of clinical presentations of systemic sclerosis and differing response to treatment,
emphasises the importance of developing means of patient stratification to ensure that
the correct patients are managed with the most appropriate treatments at a disease
duration when this will have meaningful impact on disease course and resolution. This
review aims to discuss the different means explored so far in stratifying patients with
systemic sclerosis. We highlight recent clinical trials which have applied stratification
techniques in order to provide a form of precision medicine in the management of systemic
sclerosis.
Recent findings Advances have focused on utilising gene expression techniques on whole
skin biopsies or fibroblasts to understand which groups of patients are more likely to
respond to which treatments. This technique has been used successfully to understand the
effect of tocilizumab, abatacept, and fresolimumab on systemic sclerosis, and helped
identify those that are more likely to respond to treatment.
Summary Utilising high output platforms to stratify patients for targeted treatment is still
in its infancy but has huge potential for ensuring the patients most likely to respond to a
specific therapy are put forward to trials. It has already been shown to be successful in
those with a high IL-6 profile and will most likely prove hugely informative in the future.
Introduction
Precision medicine is an evolving approach to patient-
centred care. Pioneered by cancer medicine, it aims to
integra te individual genomics , proteomics ,
pharmacogenomics, and immunogenomics informa-
tion to tailor personalised therapy, optimise efficacy,
and minimise drug toxicity [1]. By identifying key pa-
tient groups, this allows for individualised targeted ther-
apies with increased efficacy and/or reduced toxicity.
Systemic sclerosis (scleroderma; SSc) is a heteroge-
neous disease characterised by autoimmunity, vasculop-
athy and fibrosis. Traditionally considered a disease pri-
marily of the skin, the significant internal organ mani-
festations including lung fibrosis, pulmonary arterial
hypertension, gastrointestinal disease, and myositis are
responsible for the high case-specific mortality andmor-
bidity in this condition. Disease stratification within SSc
has been primarily by extent of skin involvement (lim-
ited vs diffuse), by autoantibodies [2] or by organ man-
ifestation. More modern approaches focus on the indi-
vidual disease process, which targets treatment to either
immune activation, vascular disease, or fibrosis, thus
aiding with potential targeted therapies.
Biomarkers are a means to aid stratification. The NIH
define a biomarker as Ba characteristic that is objectively
measured and evaluated as an indicator of normal bio-
logical processes, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention^ [3]. So
far, there is no validatedmolecular biomarker thatmeets
these criteria in SSc, but there aremolecular markers and
imaging which correlates with different aspects and
stages of the disease.
Lessons learned from the use of targeted treatments
in rheumatology and other immunological diseases,
combined with the heterogeneity of SSc, suggest that
only certain subgroups of patients will benefit from this
approach. Emphasis on advancing stratification and pre-
cision medicine has never been greater. Given the di-
verse clinical characteristics of this disease, many clinical
trials fail: They are either underpowered or have failed
due to the challenges of interpreting any clinical chang-
es. Ensuring the right patients who are likely to benefit
from a therapy are entered into the appropriate clinical
trial is vital if we are to prove efficacy of specific treat-
ment in SSc. This may be disease subset, stage, or organ
manifestation specific, and as advancements in molecu-
lar identification continue, this will also include specific
biomarkers and genomics hopefully to allow us to fine
tune these findings further.
In this article, we look at the different means of
stratifying SSc, and how this can be used for
personalised therapy. We will cover stratification by or-
gan manifestation, individual biomarkers, and then the
natural evolution to microarray and groups of
biomarkers.
Stratification by organ manifestation
Active skin disease
The degree of skin involvement has historically been the
main clinical tool used to stratify patients in SSc, with
limited systemic sclerosis (lcSSc) patients having skin
involvement limited to below the elbow and knee, and
diffuse SSc (dcSSc) being defined as above the elbow
and knee including chest. The modified Rodnan skin
score (mRSS) is the most frequently used outcome mea-
sure, providing a semi-quantitative evaluation of skin
thickness [4]. Rapid increase in mRSS in patients with
dcSSc is often associated with new or worsening internal
organ involvement, and correlates with increased mor-
tality [5]. The considerable inter-observer variability
means that skin score is not a reliable enough predictor
of disease severity, trajectory, or response to enable use-
ful stratification alone.
The European Scleroderma Observational Study
aimed to derive a prediction model for skin progression
in early dcSSc based on clinical characteristics. They
identified progressors (defined as an increase in 9 5 units
and 25% increase in mRSS over 12 months) as having a
shorter disease duration at time of recruitment, and
lower mRSS (although over 45% had an mRSS of 9
22). The interaction with autoantibody status also
played a significant role with anti-RNA polymerase III
patients having the highest peak skin score, and peaked
earlier compared to other autoantibody subtypes [6].
Incorporating initial skin score, with disease duration
and autoantibodies improved the accuracy of the model
in identifying high-risk patients for skin progression.
Interstitial lung disease
Clinically significant interstitial lung disease (ILD) af-
fects up to 60% of patients with SSc [7]. Diagnosis relies
on lung function tests and high-resolution chest tomog-
raphy (HRCT). Those with anti-topoisomerase I
202 Scleroderma (C Denton, Section Editor)
antibodies are at higher risk, with the presence of cen-
tromere antibodies considered protective [7]. Earlier di-
agnosis would allow earlier initiation of therapy thus
halting progression and symptomatic disease.
The recent SPAR model aimed to identify clinical
predictors of ILD progression in patients with mild ILD
at baseline (G 20% on HRCT). Validated on two inde-
pendent cohorts, lower SpO2 after the 6-min walk test
(6MWT) and arthritis were identified as independent
predictors for ILD progression [8]. Utilising these two
parameters, a SPAR score of 2 predicted a rate of ILD
progression over 85%, whereas a SPAR score of 0 was
7.4%. However, the validation cohorts did not include
anyonewith concomitant pulmonary hypertension, and
follow-up was only 1 year.
Looking at an unselected SSc cohort over a 15-year
period, variables predictive of clinically significant ILD
were greater age at disease onset, dcSSc, lower FVC and
lower diffusing capacity for carbon monoxide, and the
presence of anti-topoisomerase I antibody [7].
Three promising molecular markers in SSc-ILD
highlighted in a recent study include SP-D (surfactant
protein), KL-6 (Krebs von den Lungen-6), and CCL19.
SP-D was the superior biomarker for diagnosis, KL-6
levels correlated with severity of SSc-ILD, while CCL19
was a predictive biomarker of SSc-ILD progression [9].
Other molecularmarkers are mentioned later in the text,
but those under current investigation include mucin-1
(MUC-1), and CA15-3 which seem to be reliable predic-
tors for cases of more than 20% fibrosis, where specific
immunosuppressive therapy is considered to be indicat-
ed [10].
The PROFILE study into idiopathic pulmonary fibrosis
(IPF) identified four serum biomarkers predictive of dis-
ease progression. These were SP-D, matrix metalloprotein-
ase 7, CA19-9, and CA-125 [11]. Baseline SP-D was signif-
icantly higher in patients with progressive disease, and
rising concentrations of CA-125 were associated with in-
creased mortality. A rise in collagen degradation markers
was strongly predictive of increased mortality, with the
extent of change being associated with speed of deteriora-
tion [12]. Whether these findings are reproducible to help
predict progression in SSc-ILD remains to be clarified.
Pulmonary arterial hypertension
PAH now carries the highest mortality for patients with
SSc [13]. Survival rates are improving, with the recent
PHAROS registry reporting 93%, 75%, and 49% survival
at 1, 3, and 8 years, respectively. Significant risk factors
for poor survival were low DLCO, pericardial effusion,
decreased 6-min walk test, low cardiac index, increased
mean pulmonary artery pressure, and mean right atrial
pressure. Increased age andmale gender were poor prog-
nostic signs.
A prediction model identified greater age at onset,
increase in serum creatinine levels, lower DLCO, and the
presence of anti-RNA polymerase III or anti-U3 RNP
antibodies as associated with increased risk of pulmo-
nary hypertension [7]. The presence of anti-
topoisomerase I antibody reduced the risk of PAH.
NT-proBNP is the most studied biomarker in SSc-
PAH and has been demonstrated as a prognostic predic-
tor at baseline in PAH [14]. Changes in NT-proBNP
during follow-up aid risk stratification of patients with
SSc-PAH.However, raised concentrations of NT-proBNP
are not specific to SSc-PAH. Given that RV strain occurs
relatively late in PAH, it would be desirable to identify a
biomarker which is specific to SSc-PAH, and correlates
with early changes in PA pressure.
The DETECT score was the first evidence-based algo-
rithm for detection of patients at risk of PAH [15] and
aided in identifying the patients who may need a right
heart catheter to determine diagnosis. It utilises lung
function, ECG and echocardiography parameters, serum
urate and NTproBNP. It has high sensitivity, but a lower
specificity, thus avoiding missed diagnoses of PAH.
There is no validated tool which exists to identify pro-
gression risk or treatment response, although several
molecularmarker assessments and prediction tools have
been recently published.
VEGF-A is a regulator of angiogenesis, and con-
centrations are increased in patients with PAH [16].
In relatively small studies, VEGF-A was increased in
SSc-PAH compared to both healthy controls, and
those with SSc without PAH. Levels correlated with
systolic pulmonary arterial pressure, DLCO, and
MRC dyspnoea score. Further work is required to
understand whether VEGF-A has utility as a predic-
tive marker of PAH.
Few biomarkers have been definitive predictors of
PAH disease progression. Growth Differentiation
Factor-15 (GDF-15) clearly differentiates between SSc-
PAH and SSc without PAH, as well as correlating with
echocardiographic RVSP but not invasive hemodynam-
ics. Its evidence in idiopathic PAH is stronger for
predicting survival [17]. Thrombomodulin is another
biomarker found in higher concentrations in SSc-PAH
compared to SSc with no PAH and healthy controls [18].
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Stratification by autoantibodies
Current stratification methods in SSc rely on extent of
skin involvement and autoantibody status. Certain auto-
antibodies are associated with increased risk of internal
organ involvement (Table 1). Anti-topoisomerase (or Scl-
70) has a strong association with pulmonary fibrosis,
whereas anti-RNA-polymerase III is strongly associated
with dcSSc (up to 93% with this antibody have dcSSc),
and up to 43% of patients developing scleroderma renal
crisis (SRC). Anti-centromere antibodies (ACA) are the
commonest antibody in SSc overall, usually seen in lcSSc.
Although ACA is the commonest antibody associated
with PAH, there is no good evidence to suggest that
ACA increases the risk of developing PAH.
A classification system by Nihtyanova et al. stratifies
patients into seven main groups according to autoanti-
body and disease subtype [19]. Worst survival was seen
in Scl70+ dcSSc patients with 41% survival at 20 years.
This group had the highest incidence of ILD (91%), and
significant cardiac SSc (14%). ACA + lcSSc patients had
the highest survival (72%), and lowest incidence of ILD
(13%). The incidence of PAH was similar to the mean
for the whole cohort in this group. ARA subjects, irre-
spective of disease subtype, had the highest incidence of
SRC (32% at 20 years), and U3RNP+ patients the
highest incidence of PAH (40%) at 20 years.
Stratification by serum biomarkers
A useful biomarker for personalisedmedicine is one that
changes with time and predicts disease progression or
resolution. A number of different markers have been
investigated, and those implicated downstream of TGF-
β are often positively correlated with extent of skin
sclerosis.
TGF-β is one of the central cytokines in the patho-
genesis of SSc and has been shown to be involved in
fibrosis, inflammation, and vasculopathy in SSc [20]. Its
activity promotes collagen synthesis, secretion, process-
ing, and cross-linking, and it results in the secretion of
key matrix molecules such as fibronectin and
thrombospondin. Although it is found to be highly
expressed in the tissue samples of dcSSc patients, circu-
lating TGF-β is not consistently elevated, and thus this
makes it a less reliable biomarker.
Circulating markers correlating with skin fibrosis in-
clude interleukin-6 (IL-6) [21] and IL-13 [22]. Serum IL-6
levels have shown significant association with the extent
of skin thickness, and where elevated, there is a strong
associated withmore severe disease at 3 years and aworse
prognosis. Raised IL-6 concentrations were also predictive
of FVC and DLCO decline within the first year, and death
within the first 30 months from diagnosis [23]. Elevated
levels of PDGF were found to correlate with disease
Table 1. Antibodies associated with systemic sclerosis, the frequency of disease subtype within that antibody, and the
frequency of organ complications for each antibody. dcSSc diffuse cutaneous systemic sclerosis, LcSSc limited cutaneous
systemic sclerosis, ILD interstitial lung disease, PAH pulmonary arterial hypertension, SRC scleroderma renal crisis [2, 7, 13]
Disease subset Risk of organ involvement
Anti-centromere 95% lcSSc Digital ulceration
Anti-topoisomerase 70% dcSSc 70% ILD
Anti-RNA-Polymerase III 9 80% dcSSc 45% SRC, malignancy, PAH
Anti-U3-RNP 66% dcSSc PAH
Cardiac
31% myositis
Anti-Th/To lcSSc 25% PAH (all types)
45% lung fibrosis
Anti-Pm-Scl Overlap 9 50% muscle involvement
Anti-U1RNP 80% lcssc overlap 25% ILD
25% myositis
Overlap features
Anti-Ku Overlap 65% myositis
Anti-U11/12 Lcssc 80% lung fibrosis
82% GI involvement
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activity and lung disease [24]. IL-10 overexpression cor-
related strongly with both skin thickening, lung involve-
ment, and renal involvement. COMP (cartilage oligomer-
ic matrix protein) has been shown to have close correla-
tion with mRSS both cross-sectionally and longitudinally
[25], and acts as a predictor for mortality if measured
during the first 5 years of disease [26].
Connective tissue growth factor (CTGF) enhances fi-
broblast proliferation and acts as a downstreammediator
of TGF-β (Fig. 1). Serum CTGF correlates with extent of
skin sclerosis, as well as severity of pulmonary fibrosis, as
measured by DLCO and FVC [27]. It was suggested that
CTGF may be more involved in maintenance of fibrosis,
rather than the initiation, given levels at G 1-year disease
duration were lower than 1–3-year duration.
Elevated levels of IL-12 seem to correlate with regres-
sion of skin thickening and are found to be upregulated
in affected skin of late-stage dcSSc compared to earlier
disease, while MCP-1 and IL-6 decreased with time
[28], though this finding has not been upheld con-
sistently. IL-35, a member of the IL-12 family, has
also been shown to be negatively correlated with
disease duration, but concentrations are not corre-
lated with disease activity [29]. Emerging data sup-
port its role in disease initiation and collagen re-
lease resulting in increased fibrosis [29], but may
not be a predictor of disease response.
MCP-1 (also known as CCL2) and MCP-3 have
repeatedly been shown to have a pivotal role not only
in both skin fibrosis but also in the severity of ILD
[30, 31]. Higher serum concentrations of MCP-1 were
predictive of a faster decline in FVC in early SSc,
whereas serum IL-10 is possibly predictive of a slower
decline in FVC compared to MCP-1. Improvements in
mRSS correlate with a reduction in serum MCP-1
levels [32].
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Fig. 1. Schematic highlighting the pathogenesis of SSc, with some of the potential molecular markers used for the stratification of
disease in SSc, and their origin. KL-6 Krebs con den Lungen-6, SP-D surfactant protein D, vWF von Willebrand factor, PDGF platelet
derived growth factor, ET-1 Endothelin-1, VEGF vascular endothelial growth factor, CTGF connective tissue growth factor, NT-proBNP
N-terminal-pro B-type natriuretic peptide, GDF-15 Growth differentiation factor 15, ECM extracellular matrix, COMP cartilage
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interleukin, MCP methyl-accepting chemotaxis protein, IFNα interferon alpha, CCL C-C Motif chemokine Ligand, CXCL C-X-C motif
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Heat shock protein 70 (HSP 70) shows positive cor-
relation with MCP-1 and thus also modified Rodnan
skin score, renal vascular resistance, and pulmonary
fibrosis, and therefore may act as a supporting
serological marker for fibrosis and disease severity
with MCP-1 [33].
CXCL4 (or platelet factor 4) is another chemokine
which has been shown to predict disease progression in
SSc [34]. It is a chemotactic factor for neutrophils, fibro-
blasts and monocytes, and highly associated with lung
and skin fibrosis, and development of pulmonary arte-
rial hypertension.
Plasma Von Willebrand factor (vWf) is a marker
of endothelial cell activation, and levels have been
shown to correlate with disease severity (as mea-
sured by Medsger disease activity score), and early
pulmonary involvement. They even were able to
predict future development of elevated pulmonary
arterial pressure in lcSSc by logistic regression
models [35]. Predictors of disease onset means that
high-risk individuals can be picked up prior to
development of complications, and earlier diagno-
sis and treatment can be implicated.
These biomarkers offer the opportunity for key
predictors of disease severity and have the potential
to aid in predicting patient subgroups in order to
modify screening for organ assessment, or target
earlier interventional therapy. With time, they may
even be able to be used as predictors of treatment
response, but this remains to be confirmed. Indi-
vidual biomarkers have not proven a strong
enough association to be utilised in clinical prac-
tice yet.
Stratification by genes and gene expression
Large-scale genome-wide association studies
(GWAS) have identified several candidate genes
involved in SSc: consistently the major histocom-
patibility complex (MHC), and those involved in
regulation of innate immunity, B and T cell activa-
tion. The first robust GWAS in SSc identified the
strongest association at the 6p21 locus correspond-
ing to the MHC. It also identified five non-human
leukocyte antigen (HLA) loci: STAT4, TNPO3/IRF5,
CD247, CDH7, and EXOC2/IRF4 [36]. There is
significant overlap with other autoimmune dis-
eases, specifically CD247, a mediator of T cell re-
ceptor signalling, which is implicated in systemic
lupus erythematosus [37].
Molecular signatures in skin
Milano et al. [38] reported distinct gene expression pro-
files on skin biopsies from different subgroups of sclero-
derma patients. Broadly they were able to categorise the
profiles into four distinct groups: fibro-proliferative, in-
flammatory, limited, and normal-like. The fibro-
proliferative group largely consisted of patients with
diffuse disease, with genes associated with cell cycle
and cell growth. The inflammatory signature was seen
in a mixture of biopsies from diffuse, limited, and
morphea patients, and was categorised by immune re-
sponse and defence response genes. The limited sub-
group was predominantly limited patients with a dis-
tinct gene expression profile not otherwise expressed in
the other subsets, but did show high levels of variability.
Lastly the normal-like group consistedmainly of healthy
controls (and two SSc patients) and had increased ex-
pression of genes associated with fatty acid metabolism
and lacked any expression associated with inflammation
or proliferation.
Further work on dermal fibroblasts [39] confirmed
that the fibroproliferative set most strongly correlated
with the platelet-derived growth factor (PDGF) path-
way, thus supporting the association with cell cycle
and proliferation. The inflammatory subgroup showed
correlation with several pathways including IL4, TNFα,
and NF B expression. Both of these two subsets correlat-
ed with TGF-β expression, thus suggesting that TGF-β
signalling spans both subsets and is associated with
more severe disease [40]. Only a weak association was
seen between the inflammatory subset and interferon
alpha (IFNα) signalling pathway, and this was limited to
the patients with early disease.
There is some evidence suggesting that these subsets
may be a continuum, and patients can transition from
the inflammatory subset to the normal-like state when
their disease becomes inactive. Those in the normal-like
therefore tend to have the longest disease duration [41].
This concept was applied by Hinchcliff et al. to treat-
ment responders and non-responders. Those that re-
spond to mycophenolate mofetil (MMF) predominant-
ly expressed an inflammatory profile, whereas none of
those from the fibroproliferative subset improved on
MMF [42]. Identification of the intrinsic subset of pa-
tients with SSc therefore may help guide treatment
choice and predict those likely to respond to treatment.
Through RNA expression analysis, Farina et al. were
able to identify four key gene expression biomarkers
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which helped predict skin disease in dcSSc. These were
two TGF-β regulated genes: cartilage oligomeric matrix
protein (COMP) and thrombospondin 1 (TSP-1), as
well as interferon (IFN) regulated genes interferon-
inducible 22 (IFI44) and sialoadhesion (SIGLEC-1)
[43]. These were subsequently validated, and shown to
change over time with changes in mRSS. The impact of
this 4-gene predictor would allow for a more objective
robust measure of improvement in skin disease over
mRSS for outcome in clinical trials. Longitudinal studies
utilising microarray analysis later identified predomi-
nant clusters of gene correlating to the skin score, in-
cluding those with profibrotic/TGF-β regulated genes,
interferon-regulated/proteasome genes, macrophage
and vascular marker genes. Longitudinally THBS1 and
MS4A4A correlated best with changing skin score. IFI44
was found to have a very low correlation with mRSS
[44•]; thus, it is not consistently considered a good
predictive marker.
Mahoney et al. looked at genetic polymorphisms
identified in GWAS and the connection to intrinsic gene
expression subsets from publically available data [45].
Several gene expression modules are conserved and as-
sociated with intrinsic subsets. Network analysis of these
modules corresponding to the fibroproliferative and
inflammatory intrinsic subsets showed five distinct and
interacting subnetworks: adaptive immunity, interferon,
cell proliferation M2 macrophages, and ECM. Genes
linked to known SSc polymorphisms were found to
interact mainly within the inflammatory subnetwork
(e.g., IFR5, IRF7, IRF8, and NOTCH4), suggesting that
initiating events stem from aberrant immune responses.
The most important genes in SSc pathogenesis were
identified as either being integral in subnetwork hubs
(e.g., IFI44 for the interferon subnetwork), or connected
subnetworks (e.g., PLAUR was found to connect ECM,
M2 macrophage and adaptive immunity subnetworks).
The strongest connections in disease subgroups were
between the inflammatory and fibroproliferative intrin-
sic subsets, and these are linked via the ECM subnetwork
and TGF-β signalling.
Lofgren et al. identified a 415 gene signature of dif-
ferentially expressed genes in skin biopsies [46]. This
correlated significantly with mRSS, and any changes
between this 4S (SSc skin severity score based on differ-
ence between mean of overexpressed genes andmean of
underexpressed genes in the 415 gene set) at baseline to
12months predicted subsequent changes in skin disease
at 24 months. This still requires longitudinal validation
but has the potential to enable clinicians to identify early
treatment response and implement any changes to ther-
apy if no response is predicted.
Targeted treatments
Targeted therapy is already applied in other autoim-
mune diseases, and steps have already been made
using these techniques to target therapy to the right
subgroups of SSc.
Fresolimumab Fresolimumab is a human IgG4κ
monoclonal ant ibody which neutral i ses al l
mammalian isoforms of TGF-β. This was trialled in
patients with early dcSSc, with biomarkers of disease
activity used as the primary endpoint. There was
significant decline in THBS1 after 7 weeks of treatment
[47]. COMPwasmeasured as amarker of decreased skin
activity, and with no significant difference compared to
baseline. There was also a significant decrease in the
expression levels of SERPINE1 and CTGF, both TGF-β-
regulated genes. Fresolimumab seemed to have a greater
impact on mRSS in patients who had higher THBS1
levels at baseline.
Some patients responded more than others, so it
may be those expressing higher TGF-β signal this
targeted treatment should be applied to. Further studies
are required to confirm long-term benefit from
Fresolimumab.
Abatacept A recent small clinical trial utilising
Abatacept, a CTLA4-Ig fusion protein, compared to pla-
cebo, decreased gene expression of inflammatory path-
ways in the skin following treatment that were observed
in those that showed improvement in their mRSS. Two
placebo patients and one treatment arm patient who did
not improve over the course of the study showed stable
gene expression at the two time points (24 weeks). The
patients that did improve tended to be in the
Binflammatory intrinsic subset^ at baseline [48]. This
suggests that there is potential to target treatment based
on intrinsic subsets and therefore aid in predicting which
patient subgroups are more likely to improve or not.
Tocilizumab Another example of targeted therapy came
from the studies of IL-6 in SSc. Khan et al. identified a
cohort of patients identifiable by diffuse skin disease,
raised platelets and CRP, who had an increased IL-6
signature originating from the fibroblasts in their skin
biopsies [21].
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This led to a placebo-controlled phase II clinical
trial (faSScinate). There was a near complete reversal
of the proinflammatory gene expression profile on
skin biopsy after 6 months with the anti-IL-6 ther-
apy; however, the clinical response was not so pro-
found; with a trend towards skin improvement, and
stabilisation of lung disease [49]. Given the molec-
ular response was so profound, it raises the ques-
tion that although this targeted treatment reverses
the pro-inflammatory pathway in the explant fibro-
blasts, it most likely only stops de novo fibrosis but
is unable to reverse already established fibrosis
[50••]. Therefore, a combination therapy may be
required in this subgroup of patients. At time of
writing, the phase III trial is yet to report.
Dasatinib Dasatinib is a tyrosine kinase inhibitor with
anti-fibrotic efficacy [51], as well as inhibiting T cell
receptor signalling and the production of inflammatory
and fibrotic cytokines [52]. Gene expression data from
skin biopsies of patients treated with dasatinib for ILD
were analysed. Of those that improved (defined as
change in mRSS 9 5 points or decrease 9 20% from
baseline), their gene expression subset was consistent
with fibroproliferative or normal-like subsets, whereas
themajority of non-improvers were in the inflammatory
subset [53]. The pathways that were downregulated
post-treatment in improvers included fibrotic gene sub-
sets (e.g., PI3K/AKT/MTOR signalling and TGF-β signal-
ling), as well as inflammatory pathways including
IFNα/IFNγ response and TNFα/NF B signalling, where-
as in the non-improvers, the gene expression in these
pathways did not change.
A recent meta-analysis of clinical trials in SSc com-
pared the gene expression patterns in skin samples of
patients treated with mycophenolate mofetil, abatacept,
rituximab, fresolimumab, and nilotinib. It found that
regardless of therapy used, underpinning most clinical
improvements was a resolution of inflammatory path-
ways found in the gene expression at baseline [54•].
Treatment response was more commonly associated
with higher activity of ECM related genes, highlighting
its central role in SSc network activity. Biological differ-
ences were noted in the patients in the different therapy
subgroups and thus have the potential of being integrat-
ed to guide treatment choice. This was particularly
highlighted in the patients who did not respond to
fresolimumab and had high baseline expression of in-
flammatory pathways that were well targeted withMMF.
Franks et al. utilised their intrinsic subset and base-
line and 48/54 week serum samples to gain insight into
those who are more likely to respond to haematopoietic
stem cell transplant (HSCT) [55]. They found that par-
ticipants in the normal-like subset did not gain clinical
improvement of receiving HSCT over cyclophospha-
mide. However, those in the fibroproliferative subset
did receive the most benefit from HSCT, and this sub-
group tends to be the group they have previously report-
ed as non-responders to standard therapy (MMF or
abatacept).
These clinical findings therefore suggest that patients
that fall in the inflammatory subset should be treated
with MMF or abatacept , while those in the
fibroproliferative group are more likely to respond to
HSCT, dasatinib and fresolimumab, as are the normal-
like (but not HSCT).
Conclusion
Recent advances in high throughput analysis technologies (transcripto-
mics and proteomics) has not only broadened our understanding of
disease but allowed us to have a genome-wide view of molecular vari-
ation in disease and healthy state. They also allow for a molecular
understanding of changes in response to treatment and variations in
heterogenous disease.
Stratified and personal medicine relies on these high output platforms
providing multiplex analysis data and next-generation sequencing plat-
forms in order to understand how disease states respond to therapies,
what the changes are in those that benefit from treatment compared to
those that do not, and ultimately help in ensuring that the correct patient
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is identified who will gain benefit both at a molecular and clinical level
from these interventions, without subjecting the risks of any medication
with no perceived benefit.
Scleroderma is a heterogenous disease, and thus far no one biomarker, gene,
or gene expression data can fully explain the variability in both trajectory and
response to therapy. Gene expression profiling offers larger scale molecular
understanding of the disease process at different timepoints, with the ability
to identify patient subsets by utilising these resources. These subsets clearly
respond differently to treatments as well, and clearer stratification will identify
those most likely to respond to the disease, early signatures of treatment
response, and ultimately increase the power of a successful clinical trial. This
is all vital in order to identify the right treatment for the right patient at the right
time. This vision of stratified and personalised medicine is becoming increas-
ingly achievable and has already been applied in the use of IL-6 therapy.
Stratifying patients into those who are more likely to respond to certain thera-
pies will make a dramatic difference in clinical trials and ensure earlier access to
appropriate therapies in the near future.
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